VICTORIA, BC, Sept. 7,
2022 /CNW/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage
biotechnology company with an innovative drug delivery technology
platform, announced today that its CEO, Dr. James Helliwell, will present at the H.C.
Wainwright 24th Annual Global Investment Conference taking place on
September 12-14, 2022.
The Company's on-demand presentation will be available starting
on Monday, September 12, 2022, at
7:00 AM ET. Eupraxia invites all
interested parties to view the presentation by clicking the
following link:
https://journey.ct.events/view/3a5e62f5-8c51-4d3c-a99c-f33d0fe9aff8
A webcast of the presentation can also be accessed on the Events
and Presentations section of the Company's website here:
https://eupraxiapharma.com/investors/events-and-presentations/default.aspx
About Eupraxia
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release alternatives
to currently approved drugs. Each of Eupraxia's product candidates
has the potential to address therapeutic areas with high unmet
medical need and strives to provide improved patient benefit by
delivering targeted, long-lasting activity with fewer side
effects.
Eupraxia's lead product candidate, EP-104IAR, is currently in
Phase 2 development for the treatment of pain due to OA of the
knee. In addition to EP-104IAR, Eupraxia is developing a pipeline
of earlier-stage long-acting formulations. Potential pipeline
candidates include a range of drugs for indications such as
postsurgical pain (EP-105), and post-surgical site infections
(EP-201), each designed to improve on the activity and tolerability
of approved drugs. For further details about Eupraxia, please visit
the Company's website at: www.eupraxiapharma.com.
SOURCE Eupraxia Pharmaceuticals Inc.